1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Hepatitis B: Competitive Landscape to 2027

Hepatitis B: Competitive Landscape to 2027

  • May 2019
  • 49 pages
  • ID: 5781579
  • Format: PDF
  • GlobalData


Table of Contents

Search Inside

Hepatitis B: Competitive Landscape to 2027

Hepatitis B is a viral infection of the liver that can become chronic in young children, especially newborns to mothers with HBV infections, and people with compromised immune systems.Chronic hepatitis B is defined as measurable hepatitis B surface antigen (HBsAg) levels for more than six months after an acute infection.

Despite the existence of prophylactic vaccines, hepatitis B remains a global public health threat, with approximately 257 million people worldwide living with chronic HBV infections. Chronic hepatitis B cannot be cured and patients have elevated risks of developing liver cirrhosis and hepatocellular carcinoma (HCC).

Within the next ten years, up to six new drugs are projected to be approved for the treatment of chronic hepatitis B virus (HBV) infections in the eight major markets (8MM - US, Germany, France, Italy, Spain, the UK, Japan, and China) The HBV pipeline is heavily weighted towards small molecules and vaccines, which make up almost 60% of the drugs currently under development.

Asia-Pacific leads in HBV clinical trials; with 263 ongoing trials and China has the most drugs in the pipeline. Due to the high prevalence of chronic HBV in China, multiple companies are developing therapies specifically targeted at this market.

Despite the existence of prophylactic vaccines, hepatitis B remains a global public health threat, with approximately 257 million people worldwide living with chronic HBV.There is no cure for chronic HBV infections, but recent success in the cure of hepatitis C has re-energized the field.

The HBV pipeline is highly active, with 176 products in all stages of development, and 85% of those drugs are in early stages. Gilead Sciences is the only company that has a solid presence in HBV with its brands Viread and Vemlidy, as well as a strong pipeline featuring 36 active clinical trials.

There is a high unmet need in the finite duration of treatment with oral therapies. These drugs suppress the infection rather than eradicate it, so a new therapy that could enhance the control of the virus and long-term viral suppression would be highly advantageous.

The report “Hepatitis B: Competitive Landscape to 2027” provides an assessment of the pipeline, clinical, and commercial landscape of Hepatitis B. Overall, it is expected that the new drug approvals would improve the treatment options of Hepatitis B over the next decade (2017-2027).

GlobalData’s Hepatitis B: Competitive Landscape to 2027 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the slide deck include -
- Pipeline Assessment—regional breakdown, promising late-stage products, early-stage pipeline by product type
- Clinical Trials Assessment—trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
- Commercial Assessment—leading marketed products, current and future players
- Competitive Landscape Analysis—key market events (2017-2027)

Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global seasonal influenza market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global seasonal influenza market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Blood Products Markets in China

  • $ 4000
  • June 2021
  • 274 pages

China’s demand for Blood Products has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth ...

  • China
  • United States
  • Vaccine
  • Healthcare
  • Industry analysis
  • Industrial Production
  • Labour Force


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on